These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 25814078)

  • 41. Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib.
    Castagnetti F; Gugliotta G; Breccia M; Stagno F; Iurlo A; Albano F; Abruzzese E; Martino B; Levato L; Intermesoli T; Pregno P; Rossi G; Gherlinzoni F; Leoni P; Cavazzini F; Venturi C; Soverini S; Testoni N; Alimena G; Cavo M; Martinelli G; Pane F; Saglio G; Rosti G; Baccarani M;
    Leukemia; 2015 Sep; 29(9):1823-31. PubMed ID: 26088952
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Rationale and motivating factors for treatment-free remission in chronic myeloid leukemia.
    Caldemeyer L; Akard LP
    Leuk Lymphoma; 2016 Dec; 57(12):2739-2751. PubMed ID: 27562641
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Response-related predictors of survival in CML.
    Hanfstein B; Müller MC; Hochhaus A
    Ann Hematol; 2015 Apr; 94 Suppl 2():S227-39. PubMed ID: 25814089
    [TBL] [Abstract][Full Text] [Related]  

  • 44. New insights into biology of chronic myeloid leukemia: implications in therapy.
    Cea M; Cagnetta A; Nencioni A; Gobbi M; Patrone F
    Curr Cancer Drug Targets; 2013 Sep; 13(7):711-23. PubMed ID: 23906052
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Sequencing treatment in chronic myeloid leukemia: the first choice may be the hardest.
    Heaney ML
    Clin Adv Hematol Oncol; 2014 Aug; 12(8):502-8. PubMed ID: 25356574
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A population-based study of chronic myeloid leukemia patients treated with imatinib in first line.
    Castagnetti F; Di Raimondo F; De Vivo A; Spitaleri A; Gugliotta G; Fabbiano F; Capodanno I; Mannina D; Salvucci M; Antolino A; Marasca R; Musso M; Crugnola M; Impera S; Trabacchi E; Musolino C; Cavazzini F; Mineo G; Tosi P; Tomaselli C; Rizzo M; Siragusa S; Fogli M; Ragionieri R; Zironi A; Soverini S; Martinelli G; Cavo M; Vigneri P; Stagno F; Rosti G; Baccarani M
    Am J Hematol; 2017 Jan; 92(1):82-87. PubMed ID: 27770583
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Management of adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukemia.
    Rea D
    Ann Hematol; 2015 Apr; 94 Suppl 2():S149-58. PubMed ID: 25814081
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The expanding options for front-line treatment in patients with newly diagnosed CML.
    Pinilla-Ibarz J; Flinn I
    Crit Rev Oncol Hematol; 2012 Nov; 84(2):287-99. PubMed ID: 22487423
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Milestones and monitoring.
    Morotti A; Fava C; Saglio G
    Curr Hematol Malig Rep; 2015 Jun; 10(2):167-72. PubMed ID: 25921389
    [TBL] [Abstract][Full Text] [Related]  

  • 50. How to choose frontline therapy for chronic myelogenous leukemia: so many drugs, not so many patients.
    Shami PJ
    J Natl Compr Canc Netw; 2012 Jan; 10(1):112-8; quiz 119. PubMed ID: 22223871
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tyrosine kinase inhibitors for elderly chronic myeloid leukemia patients: a systematic review of efficacy and safety data.
    Breccia M; Tiribelli M; Alimena G
    Crit Rev Oncol Hematol; 2012 Oct; 84(1):93-100. PubMed ID: 22280914
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Is cure for chronic myeloid leukemia possible in the tyrosine kinase inhibitors era?
    Bansal A; Radich J
    Curr Opin Hematol; 2016 Mar; 23(2):115-20. PubMed ID: 26825700
    [TBL] [Abstract][Full Text] [Related]  

  • 53. NCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemia.
    O'Brien S; Berman E; Moore JO; Pinilla-Ibarz J; Radich JP; Shami PJ; Smith BD; Snyder DS; Sundar HM; Talpaz M; Wetzler M
    J Natl Compr Canc Netw; 2011 Feb; 9 Suppl 2(0 2):S1-25. PubMed ID: 21335443
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The role of hematopoietic stem cell transplantation in chronic myeloid leukemia.
    Gratwohl A; Baldomero H; Passweg J
    Ann Hematol; 2015 Apr; 94 Suppl 2():S177-86. PubMed ID: 25814084
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prolonged Survival of a Patient with Chronic Myeloid Leukemia in Accelerated Phase with Recurrent Isolated Central Nervous System Blast Crisis.
    Bin Salman AA; Zaidi ARZ; Altaf SY; AlShehry NF; Tailor IK; Motabi IH; Zaidi SZA
    Am J Case Rep; 2020 Sep; 21():e922971. PubMed ID: 32920590
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Molecular monitoring of chronic myeloid leukemia: principles and interlaboratory standardization.
    Cross NC; Hochhaus A; Müller MC
    Ann Hematol; 2015 Apr; 94 Suppl 2():S219-25. PubMed ID: 25814088
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Practical issues surrounding the explosion of tyrosine kinase inhibitors for the management of chronic myeloid leukemia.
    Mathisen MS; Kantarjian HM; Cortes J; Jabbour EJ
    Blood Rev; 2014 Sep; 28(5):179-87. PubMed ID: 24984571
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The Role of Early Molecular Response in the Management of Chronic Phase CML.
    Harrington P; Kizilors A; de Lavallade H
    Curr Hematol Malig Rep; 2017 Apr; 12(2):79-84. PubMed ID: 28405921
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Successful Use of Dasatinib After Liver Transplantation for Imatinib-Induced Fulminant Liver Failure in Chronic Myeloid Leukemia.
    Harding DJ; MacQuillan G; Howman R; de Boer B; Adams L; Mitchell A; Jeffrey G
    J Clin Oncol; 2016 Apr; 34(11):e97-8. PubMed ID: 25267743
    [No Abstract]   [Full Text] [Related]  

  • 60. Towards a Personalized Treatment of Patients with Chronic Myeloid Leukemia.
    Rabian F; Lengline E; Rea D
    Curr Hematol Malig Rep; 2019 Dec; 14(6):492-500. PubMed ID: 31760572
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.